An alternative strategy is to target multiple nodes on a signalling network simultaneously giving the cancer cell a higher evolutionary barrier to overcome in order to achieve resistance.16, 17 Although the highly conserved active site of protein kinases is often cited as a cause of poor selectivity of kinase inhibitors, it may be possible to exploit this poor selectivity to target multiple kinases.12 The gene discussed is WEE1; the disease is cancer.